Literature DB >> 17307325

Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate.

J Kuhn1, H Bewermeyer, H Miyajima, Y Takahashi, K F Kuhn, T U Hoogenraad.   

Abstract

Aceruloplasminemia is an autosomal recessive and phenotypically primarily neurodegenerative disease caused by a homozygous mutation of the ceruloplasmin gene. The absence of ceruloplasmin and its ferroxidase activity leads to pathological iron overload in the brain and other organs. While heterozygous carriers of ceruloplasmin gene mutations have been believed to be asymptomatic, a number of cases with neurological deficits have recently been described. To date, an effective treatment has not been established for either aceruloplasminemia or symptomatic heterozygous aceruloplasminemia. The present report concerns the beneficial treatment of an 18-year-old girl with extrapyramidal and cerebellar-mediated movement disorder caused by a heterozygous mutation of the ceruloplasmin gene using oral zinc sulphate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307325     DOI: 10.1016/j.braindev.2007.01.001

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  12 in total

1.  Multiple motor system dysfunction associated with a heterozygous ceruloplasmin gene mutation.

Authors:  Adolfo Jiménez-Huete; Juan Bernar; Hiroaki Miyajima; Yoshitomo Takahashi; Juan Alvarez-Linera; Oriol Franch; Marjo S van der Knaap
Journal:  J Neurol       Date:  2008-02-25       Impact factor: 4.849

2.  Aceruloplasminemia: a case report.

Authors:  Domenico Di Raimondo; Antonio Pinto; Antonino Tuttolomondo; Paola Fernandez; Clara Camaschella; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2008-04-12       Impact factor: 3.397

Review 3.  Aceruloplasminaemia: a rare but important cause of iron overload.

Authors:  Adam Doyle; Ferry Rusli; Prithi Bhathal
Journal:  BMJ Case Rep       Date:  2015-05-14

4.  Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment.

Authors:  L Poli; A Alberici; P Buzzi; E Marchina; A Lanari; C Arosio; A Ciccone; F Semeraro; R Gasparotti; A Padovani; Barbara Borroni
Journal:  Neurol Sci       Date:  2016-11-05       Impact factor: 3.307

Review 5.  Iron in chronic brain disorders: imaging and neurotherapeutic implications.

Authors:  James Stankiewicz; S Scott Panter; Mohit Neema; Ashish Arora; Courtney E Batt; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

6.  Reactive oxygen species are involved in ferroportin degradation induced by ceruloplasmin mutant Arg701Trp.

Authors:  Tiziana Persichini; Giovanni De Francesco; Caterina Capone; Antimo Cutone; Maria Carmela Bonaccorsi di Patti; Marco Colasanti; Giovanni Musci
Journal:  Neurochem Int       Date:  2012-01-20       Impact factor: 3.921

7.  Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.

Authors:  Armin Finkenstedt; Elisabeth Wolf; Elmar Höfner; Bethina Isasi Gasser; Sylvia Bösch; Rania Bakry; Marc Creus; Christian Kremser; Michael Schocke; Milan Theurl; Patrizia Moser; Melanie Schranz; Guenther Bonn; Werner Poewe; Wolfgang Vogel; Andreas R Janecke; Heinz Zoller
Journal:  J Hepatol       Date:  2010-08-04       Impact factor: 25.083

8.  Aceruloplasminemia with Abnormal Compound Heterozygous Mutations Developed Neurological Dysfunction during Phlebotomy Therapy.

Authors:  Maki Watanabe; Ken Ohyama; Masashi Suzuki; Yasunobu Nosaki; Takashi Hara; Katsushige Iwai; Satoshi Kono; Hiroaki Miyajima; Kenji Mokuno
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

Review 9.  Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.

Authors:  Vassilena Iankova; Ivan Karin; Thomas Klopstock; Susanne A Schneider
Journal:  Front Neurol       Date:  2021-04-15       Impact factor: 4.003

10.  Genetic and Clinical Heterogeneity in Thirteen New Cases with Aceruloplasminemia. Atypical Anemia as a Clue for an Early Diagnosis.

Authors:  Marc Vila Cuenca; Giacomo Marchi; Anna Barqué; Clara Esteban-Jurado; Alessandro Marchetto; Alejandro Giorgetti; Viorica Chelban; Henry Houlden; Nicholas W Wood; Chiara Piubelli; Marina Dorigatti Borges; Dulcinéia Martins de Albuquerque; Kleber Yotsumoto Fertrin; Ester Jové-Buxeda; Jordi Sanchez-Delgado; Neus Baena-Díez; Birute Burnyte; Algirdas Utkus; Fabiana Busti; Gintaras Kaubrys; Eda Suku; Kamil Kowalczyk; Bartosz Karaszewski; John B Porter; Sally Pollard; Perla Eleftheriou; Patricia Bignell; Domenico Girelli; Mayka Sanchez
Journal:  Int J Mol Sci       Date:  2020-03-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.